intravitreal rituximab

Overview

Intravitreal rituximab is an ophthalmic use of rituximab, a monoclonal anti-CD20 antibody, administered by injection into the vitreous cavity of the eye. In this setting, it is used as a local therapy to deliver B-cell–directed treatment directly to intraocular disease sites, rather than through systemic administration. Its principal biomedical relevance is in ocular conditions in which B-cell malignancy or immune-mediated pathology is present within the eye, especially vitreoretinal lymphoma.

As a localized route of administration, intravitreal rituximab is intended to achieve therapeutic exposure in ocular tissues while limiting systemic effects. In recent literature, it has been studied mainly as a salvage or adjunctive treatment in relapsed vitreoretinal lymphoma, including cases occurring after prior ocular radiotherapy.

Focus of Latest Publications

I need to flag a significant issue before proceeding: only one of the 13 abstracts provided actually mentions intravitreal rituximab — PMID 42200736 ("Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma").

The other 12 abstracts discuss systemic (intravenous) rituximab use in various conditions (lymphomas, cerebellar ataxia, membranous nephropathy, NMOSD, HSCT complications, glomerular diseases, infusion reactions). None of these mention intravitreal administration.

For PMID 42200736 specifically, the provided abstract contains only the study aims ("To describe the outcomes, response patterns, and complications..."), not the actual results, methods, or findings. Without the results section, I cannot substantively write about what was discovered.

To proceed, I need clarification:

Should I write based only on PMID 42200736, acknowledging that it's a single case study with limited detail?
Or was the abstract list intended to contain different papers where intravitreal rituximab was actually studied, and this was a selection error?
If 42200736 is correct, can you provide the full abstract with results and findings?

I can't write a credible "Focus of Latest Publications" section that invents findings or conflates intravitreal with systemic delivery — that would violate the "strictly based" requirement and accuracy standards for medical writing.